Launxp Biomedical Co Ltd banner

Intrinsic Value

Not Available for Launxp Biomedical Co Ltd

There is not enough data to reliably calculate the intrinsic value for Launxp Biomedical Co Ltd.

Do our valuations actually work? See backtest results .

Alternatives to Launxp Biomedical Co Ltd

Fundamental Analysis

What Launxp Biomedical Does

Pharmaceuticals Health Care

LAUNXP Biomedical Co. Ltd. is engaged in the development of medicines for tumor therapies. The company is headquartered in Taichung, Taichung. The company went IPO on 2024-01-18. The firm mainly develops cancer drugs. The main products include LXPA1788, LXPA1988, LXPA5948, LXPB5268, LXPB5101, LXPB8101, LXPB9568, LXPB977 and others. LXPA1788 is a new ingredient and new drug, a multi-target kinase inhibitor.

Headquarters
Taiwan TW
Employees
35
IPO date
Jan 18, 2024
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Past 12 months

Continue Research

Decided on Launxp Biomedical? Get an email when Launxp Biomedical Co Ltd reaches the price you’d buy at. Free with an account.

Back to Top